Coherus Plots ‘Lowest Price Adalimumab’ With Huge Discount, Ties Up With Mark Cuban
California-Based Firm Unveils Two Major Pricing Strategies For Humira Biosimilar
Coherus BioSciences had teased a “compelling value proposition” for its Yusimry (adalimumab-aqvh) biosimilar to AbbVie’s Humira blockbuster and it has delivered, with a pair of pricing strategies include one though an alliance with self-labelled “disruptor” Mark Cuban.
You may also be interested in...
Self-labelled ‘disruptor’ Mark Cuban has brought on board yet another high-demand prescription drug, following a recent deal for biosimilar Humira.
Coherus BioSciences has welcomed an uplift of sales for its ranibizumab biosimilar, as well as discussing its efforts to reinvigorate its pegfilgrastim biosimilar franchise, during the company’s second-quarter earnings call.
Coherus has made deals with numerous pharmacy benefit managers and pharmacies to bring its low list price Yusimry adalimumab biosimilar to patients, as analysts continue to back Humira originator AbbVie as market leader.